Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan

Hypertension Research

Volumn 37, Issue 7, 2014, Pages 616-620

  Iwanami, Jun ^a   Mogi, Masaki ^a   Tsukuda, Kana ^a   Wang, Xiao Li ^a   Nakaoka, Hirotomo ^a   Ohshima, Kousei ^a   Chisaka, Toshiyuki ^a   Bai, Hui Yu ^a   Kanno, Harumi ^a   Min, Li Juan ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiotensin II type 1 receptor; angiotensin (1'7); angiotensin converting enzyme 2

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; AZILSARTAN; MESSENGER RNA; OLMESARTAN; RENIN; SODIUM ION; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; EPITHELIAL SODIUM CHANNEL; G PROTEIN COUPLED RECEPTOR; IMIDAZOLE DERIVATIVE; ONCOPROTEIN; OXADIAZOLE DERIVATIVE; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1; SODIUM; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HUMAN; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TELEMETRY; WILD TYPE; ANIMAL; BLOOD PRESSURE; C57BL MOUSE; CARDIOMEGALY; DRUG EFFECTS; GENETICS; PHYSIOLOGY; URINE;

ANGIOTENSIN I; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CARDIOMEGALY; EPITHELIAL SODIUM CHANNELS; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; OXADIAZOLES; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SODIUM; TETRAZOLES;

EID: 84901407004     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.49     Document Type: Article

References (28)

1. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, Raizada MK. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010; 55: 207-213.
2. Passos-Silva DG, Verano-Braga T, Santos RA. Angiotensin-(1-7): beyond the cardiorenal actions. Clin Sci (Lond) 2013; 124: 443-456.
3. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 2006; 290: H684-H691.
4. Giani JF, Muñ oz MC, Pons RA, Cao G, Toblli JE, Turyn D, Dominici FP. Angiotensin-(1- 7) reduces proteinuria and diminishes structural damage in renal tissue of strokeprone spontaneously hypertensive rats. Am J Physiol Renal Physiol 2011; 300: F272-F282.
5. Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K, Murakami K. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 1993; 268: 11617-11621.
6. Sevá Pessôa B, van der Lubbe N, Verdonk K, Roks AJ, Hoorn EJ, Danser AH. Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol 2013; 9: 26-36.
7. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289: H1013-H1019.
8. Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/ p38 MAP kinase pathway. Am J Pathol 2008; 172: 1174-1183.
9. Gallagher PE, Ferrario CM, Tallant EA. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol 2008; 295: C1169-C1174.
10. Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 2008; 295: H2373-H2379.
11. Iwai M, Nakaoka H, Senba I, Kanno H, Moritani T, Horiuchi M. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling. Hypertension 2012; 60: 137-144.
12. Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, Nagaya H. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336: 801-808.
13. Bönner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, Handley A, Kupfer S. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27: 479-486.
14. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-420.
15. Mills PA, Huetteman DA, Brockway BP, Zwiers LM, Gelsema AJ, Schwartz RS, Kramer K. A new method for measurement of blood pressure, heart rate, and activity in the mouse by radiotelemetry. J Appl Physiol 2000; 88: 1537-1544.
16. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptor in the kidney. Proc Natl Acad Sci USA 2006; 103: 17985-17990.
17. Crowley SD, Zhang J, Herrera M, Griffiths R, Ruiz P, Coffman TM. Role of AT1 receptormediated salt retention in angiotensin II-dependent hypertension. Am J Physiol Renal Physiol 2011; 301: F1124-F1130.
18. Mamenko M, Zaika O, Ilatovskaya DV, Staruschenko A, Pochynyuk O. Angiotensin II increases activity of the epithelial Na' channel (ENaC) in distal nephron additively to aldosterone. J Biol Chem 2012; 287: 660-671.
19. Bürgelová M, Vanourková Z, Thumová M, Dvorák P, Opocenský M, Kramer HJ, Zelízko M, Malý J, Bader M, Cervenka L. Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension. J Hypertens 2009; 27: 1988-2000.
20. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR, Ulick S, Milora RV, Findling JW, Canessa CM, Rossier BC, Lifton RP. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79: 407-414.
21. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, Schild L, Lu Y, Shimkets RA, Nelson-Williams C, Rossier BC, Lifton RP. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996; 12: 248-253.
22. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43: 970-976.
23. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination reninangiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) 2012; 123: 649-658.
24. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-2610.
25. Moritani T, Iwai M, Kanno H, Nakaoka H, Iwanami J, Higaki T, Ishii E, Horiuchi M. ACE2 deficiency induced perivascular fibrosis and cardiac hypertrophy during postnatal development in mice. J Am Soc Hypertens 2013; 7: 259-266.
26. Inaba S, Iwai M, Furuno M, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M. Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. J Hypertens 2011; 29: 2236-2245.
27. Shiota A, Yamamoto K, Ohishi M, Tatara Y, Ohnishi M, Maekawa Y, Iwamoto Y, Takeda M, Rakugi H. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertens Res 2010; 33: 298-307.
28. Varagic J, Ahmad S, VonCannon JL, Moniwa N, Brosnihan KB, Wysocki J, Batlle D, Ferrario CM. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats. Am J Hypertens 2013; 26: 583-590.